Companies › Ambros Therapeutics
1 active drug program in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMBTX-01 (Neridronate) Bisphosphonate | – | Phase 3 | Complex Regional Pain Syndrome Type I | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07210515 | AMBTX-01 (Neridronate) | Phase 3 | Complex Regional Pain Syndrome Type I | Neurology | Dec 2027 |
| NCT07857733 | AMBTX-01 (Neridronate) | Phase 3 | Complex Regional Pain Syndrome Type I | Neurology | Dec 2028 |
No annotated target.
–
Prilenia Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.